Case Report ARTICLE
Darbepoetin alfa in young infants with renal failure: single center experience, a case series and review of the literature
- 1Department of Woman-Mother-Child, Lausanne University Hospital, Switzerland
- 2CHUV Centre de transplantation orgue, Switzerland
Anemia treatment in infants with advanced or chronic kidney disease (CKD) represents an important challenge. The use of darbepoetin alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human erythropoietin in older children and in adults with CKD. However, studies reporting the use of darbepoetin alfa in infants below 1 year of age are sparse.
We report the data of three infants with advanced stage kidney failure, aged 1, 4 and 7 months, who were treated with darbepoetin alfa and followed for 18 to 41 months. Hemoglobin levels increased in all 3 patients, reaching the target levels of 10.7-12 g/dl by 11, 19 and 22 weeks respectively, without any documented adverse effects. Patients younger than 1 year of age required a larger darbepoetin alfa dosage (ranged from 1.2 to 2.9 μg/kg per month) as compared to older children. A review of the literature found only 3 studies using darbepoetin alfa successfully in such young infants.
In these 3 patients with advanced kidney disease, darbepoetin alfa was effective in correcting anemia with no observed adverse effects.
Keywords: Anemia, chronic kidney disease, Darbepoeitin alfa, Chronic Kidney Disease, Infant - age, pediatric
Received: 24 Jul 2018;
Accepted: 30 Nov 2018.
Edited by:Douglas M. Silverstein, United States Food and Drug Administration, United States
Reviewed by:Kimberly J. Reidy, Montefiore Medical Center, United States
Aftab S. Chishti, University of Kentucky, United States
Copyright: © 2018 Libudzic-Nowak, Cachat, Pascual and Chehade. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Hassib Chehade, Department of Woman-Mother-Child, Lausanne University Hospital, Lausanne, Vaud, Switzerland, Hassib.email@example.com